starting dose of retatrutide VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide 10 mg: vial guide

Off-Label Promotion and Ethical Implications The aggressive marketing strategies employed to promote GLP-1 agonists for weight loss prior to obtaining formal regulatory approval for such indications raise significant ethical and legal questions

A decade from now, the most popular GLP-1 drugs might advertise weight loss as a secondary benefit

Additionally, the expiration of patents for blockbuster GLP-1 therapeutics, such as semaglutide, is stimulating the market for generics and biosimilars

Global Manufacturing Standards Produced in WHO-& ISO13485:2016 certified facilities

[DOI] [PubMed] [Google Scholar] Balenovic I, Barisic I, Prkacin I, et al